Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Autor: D. Miles, J. Gligorov, F. André, D. Cameron, A. Schneeweiss, C. Barrios, B. Xu, A. Wardley, D. Kaen, L. Andrade, V. Semiglazov, M. Reinisch, S. Patel, M. Patre, L. Morales, S.L. Patel, M. Kaul, T. Barata, J. O’Shaughnessy, Q. Zhang, Z. Shao, X. Wang, C. Geng, X. Yan, Z. Tong, K. Shen, Y. Yin, T. Sun, J. Yang, J. Feng, M. Yan, Y. Wang, Q. Liu, S. Zhang, M. De Laurentiis, A. Santoro, V. Guarneri, M. Colleoni, C. Natoli, L. Cortesi, S. Placido, L. Gianni, F. Ferrau, L. Livi, A. Zambelli, L. Del Mastro, G. Tonini, F. Montemurro, G. Bianchi, R. Pedersini, S. Prete, G. Allegrini, G. Naso, P. Vici, D. Loirat, A. Mailliez, F. Priou, O. Tredan, F. Dalenc, C. Perrin, M. Timar David, N. Dohollou, L. Teixeira, F. Brocard, A. Arnaud, S. Delaloge, J.-P. Spano, L. Mansi, F. Damian, J. Pedrini, S. Aleixo, R. Hegg, R. Junior, M. Schmidt, C. Wenzel, E.-M. Grischke, M. Just, N. Harbeck, C. Schumacher, U. Peters, D. Fischer, H. Forstbauer, R. Liersch, E. Warner, N. Bouganim, C. Doyle, J. Price Hiller, T. Vandenberg, M. Pavic, A. Robinson, G. Roldan Urgoiti, N. Califaretti, A. Alacacioglu, M. Gumus, B. Yalcin, I. Cicin, F. Kose, K. Uygun, M. Kaplan, E. Cubukcu, M. Harries, D. Doval, S. Gupta, P. Mohapatra, S. Chatterjee, N. Ghadyalpatil, M. Singhal, S. Nag, A. Agarwal, I. Wolf, E. Gal Yam, R. Yerushalmi, T. Peretz, G. Fried, N. Ben Baruch, D. Katz, E. Hamilton, F. Kayali, A. Brufsky, M. Telli, G. Wright, R. Oyola, T. Rakowski, S. Graff, S. Tjulandin, A. Aparicio, M. Ruiz Borrego, L. Merino, J. Guerra Martinez, E. Lopez, T. Yamashita, S. Ohtani, K. Inoue, Y. Ito, N. Niikura, T. Nakayama, Y. Sagara, Y. Yanagita, Y. Kamada, K. Kaneko, A. Nervo, A. Eniu, M. Schenker, P. Priester, B. Melichar, M. Zimovjanova, P. Sormova, J. Sufliarsky, M. Kakalejcik, R. Belbaraka, H. Errihani, D. Le Than, D. Pham, G. Aravantinos, C. Papadimitriou, G. Koumakis, C. Papandreou, P. Podolski, K. Tabane

Background In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df6f5901fe141d7f4c234b96423f14d
http://hdl.handle.net/11577/3456729

Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial

Autor: Vincent Houe, Paulo M. Hoff, Karen Afenjar, J. Price Hiller, Alberto Sobrero, DJ Slamon, Saba Khan-Wasti, Shukui Qin, Andrew Scarfe, Jennifer L. Spratlin, Karen E. Mulder, Neil Chua, Sheryl Koski, J.R. Hecht, Michael Patvin Chu, A. Fontaine, Michael B. Sawyer, Yingjie Huang, Y-J. Bang, Karen King

Publikováno v: Annals of Oncology. 25:iv211

Aim: Cape is used to treat GI and other malignancies. Oral drug absorption often relies on pH-dependent solubility. Many GEC patients (pts) take PPIs for symptom control, which increases gastric pH and PPIs have been shown to impact other anti-cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97de8a2a55ed7387ad58588bd6ff9502
https://doi.org/10.1093/annonc/mdu334.6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.